Cinarin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinarin

Property Description
Active ingredient Cinnarizine
Form Oral Tablet
Pharmacological class Antihistamine and Calcium Channel Blocker
Common use Relief of symptoms related to disequilibrium and vertigo
Origin Synthetic Small Molecule

What Type of Medicine is Cinnarizine?

Cinnarizine is the active compound in the medicinal preparation often known as Cinarin, chemically classified as both a Histamine H1 Antagonist and a Calcium Channel Blocker (Calcium Channel Antagonist). This pharmaceutical agent is a synthetic small molecule provided for oral use, typically in the dosage form of a tablet. Cinnarizine is a single-ingredient product, meaning its therapeutic effect stems solely from this one active substance, differentiating it from combination medications. Cinnarizine is recognized for its ability to affect the vestibular system and has an established use in the management of vestibular disorders. This medicine helps ease discomfort by stabilizing the inner ear's balance mechanisms. Popular brands containing this identical formulation include Stugeron and Vertiron, which position Cinnarizine for addressing motion sensitivity in diverse patient groups.

What is the General Purpose of Cinnarizine?

The general purpose of Cinnarizine is to mitigate symptoms of disequilibrium by balancing the inner ear and improving circulation to relevant areas. This therapeutic objective is achieved through a combined action that involves vestibular suppression and improved localized microcirculation. The drug acts as a vestibular sedative, effectively dampening the sensory signals transmitted from the labyrinth, the inner ear structure responsible for detecting motion and gravity. The compound's role as a Calcium Channel Blocker helps relax the smooth muscles of small blood vessels, particularly in the cerebral and inner ear regions, thereby supporting adequate blood flow. This mechanism has led to Cinnarizine being classified as an antivertigo preparation under the Anatomical Therapeutic Chemical (ATC) classification system. Cinnarizine is recognized for its general role in addressing dizziness and imbalance, such as relieving nausea associated with travel or changes in head position.

What side effects are possible with Cinarin?

Cinarin (also known as Cinnarizine) is associated with a defined profile of adverse reactions and safety considerations documented in regulatory product information.

Adverse Reactions

The most frequently reported adverse reactions are typically mild and transient, primarily affecting the central nervous system and gastrointestinal tract.

  • Very Common / Common Reactions: Drowsiness (somnolence), nausea, and weight gain are the most commonly cited adverse effects in pooled clinical data.
  • Other Reported Reactions: Less common effects include headache, gastrointestinal upset (such as abdominal pain or vomiting), and symptoms like dry mouth.

Serious Safety Considerations

A few safety elements require particular attention, especially with prolonged use or in specific populations:

  • Extrapyramidal Symptoms: These include slow, twitchy, or jerky body movements, muscle stiffness, and tremor (shaking). They are a significant risk, particularly for elderly patients and with long-term therapy. This drug-induced parkinsonism may be irreversible in some cases, necessitating caution and monitoring.
  • Hypersensitivity: Rare but severe allergic reactions (anaphylaxis) can occur, requiring immediate medical attention.
  • Hepatic Reactions: Extremely rare instances of liver problems, such as jaundice (yellowing of the skin/eyes), have been documented.

Safety Restrictions and Special Populations

  • Driving and Operating Machinery: Due to the risk of drowsiness, especially at the start of treatment, patients are advised against driving or operating heavy machinery if affected.
  • Contraindications: The medicine is generally contraindicated in patients with known hypersensitivity to the drug.
  • Elderly Patients: This population is at a heightened risk for developing serious extrapyramidal symptoms and must be carefully monitored, especially during prolonged use.
  • Overdose: Acute overdose has been linked to severe central nervous system symptoms, including alterations in consciousness (somnolence to coma), vomiting, extrapyramidal symptoms, and, in young children, seizures. Overdose can be fatal and requires immediate medical intervention.

This information represents the documented risk profile and regulatory safety framework for Cinarin.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cinnarizine overdose, based on established government prescribing information, describes several documented manifestations and the required emergency response. Overdose typically presents with central nervous system depression, including symptoms ranging from somnolence and stupor to coma. Gastrointestinal effects, such as vomiting, and motor disturbances, including extrapyramidal symptoms, are also listed as common clinical signs.

Required Emergency Action

Immediate medical attention is required due to the potential for severe outcomes, including reported fatalities, following both single and polydrug ingestions. Regulatory documents advise contacting a poison control centre for current management recommendations.

Management and Specific Risks

Treatment is entirely symptomatic and supportive, as no specific antidote is known. Officially documented risks include the development of seizures or convulsions in a small number of young children. For pediatric patients, regulatory guidance notes that hospital observation in a healthcare facility is necessary due to the potential for neurological complications. Decontamination procedures, such as the use of activated charcoal or gastric lavage, are supportive options mentioned in the official context of overdose management.

Therapeutic Uses of Cinarin

This medication is commonly used to address symptoms related to inner ear function and motion sensitivity, providing supportive relief in relevant therapeutic domains.


Easing Vertigo and Chronic Inner Ear Symptoms

Cinnarizine is used for managing symptoms of vestibular disorders and disturbances within the inner ear, such as conditions like Ménière's disease. It helps address symptom clusters that may become intense or disruptive, including pronounced vertigo, persistent dizziness, unsteadiness, and co-occurring tinnitus. This approach is generally applied in situations involving episodic or chronic symptom patterns, which supports the patient during difficult episodes by easing distress.

“This medicine is considered relevant for managing symptoms that interfere with daily comfort and stability, particularly those associated with inner ear function.”

Reducing Motion-Induced Sickness and Associated Nausea

This medication is considered relevant for addressing symptoms specifically triggered by motion, commonly known as motion sickness or travel sickness. It is frequently applied in scenarios where additional management of discomfort is required, such as before and during travel, to manage the symptoms that may appear during travel, including nausea and vomiting. This supportive benefit helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms and assisting with maintaining functional stability.

Quick Fact: Relief for Inner Ear Imbalance Cinnarizine is often used across conditions where the primary distress arises from a combination of persistent dizziness, unsteadiness, and accompanying symptoms like nausea or vomiting, providing targeted symptomatic assistance.

Eligibility and Restrictions for Use

The official eligibility for Cinnarizine is strictly defined by regulatory documents, establishing three categories of use: allowed, restricted, or contraindicated.

Absolute Non-Eligibility (Contraindicated)

Cinnarizine is formally contraindicated and must not be used in patients with known Hypersensitivity to the active substance or any of its excipients. Use is also absolutely prohibited for patients diagnosed with Porphyria, an inherited blood condition.

Conditional and Restricted Use

Use is conditional for certain groups, requiring special consideration. Patients with Parkinson’s Disease should only use Cinnarizine if the therapeutic advantages outweigh the risk of aggravating their condition. Caution is also advised for patients with hepatic insufficiency or renal insufficiency. The medicine may be used in the elderly, but caution is recommended during prolonged use.

Age and Life Stage Limitations

The medicine is not recommended for use in children under 5 years old. Furthermore, Cinnarizine is not advised during pregnancy (as safety has not been established) and is not recommended for women who are breastfeeding due to a lack of data on its excretion in human milk.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Cinnarizine centers on pharmacodynamic reinforcement and administration requirements, with no specific pharmacokinetic (CYP-mediated or transporter-based) interactions officially documented.

Interaction Scope

Category Documented Information
Interacting Categories Central Nervous System (CNS) depressants, Tricyclic Antidepressants, Alcohol
Mechanistic Basis Pharmacodynamic reinforcement (additive CNS depressant effect)
Timing-based Rule Discontinuation required prior to dermal reactivity indicators (skin allergy tests)
Population Note Use with caution advised in hepatic insufficiency and renal insufficiency

Official Interaction Statements

  • Potentiation of Sedation: Concurrent use of Alcohol, Central Nervous System (CNS) depressants, or Tricyclic Antidepressants may officially potentiate the sedative effects of Cinnarizine or the co-administered substance. This is an additive pharmacodynamic interaction.
  • Diagnostic Procedural Constraint: Cinnarizine's antihistamine activity may interfere with the results of dermal reactivity indicators; regulatory documents mandate that the medicine be withheld within four days prior to such testing to avoid preventing a positive reaction.
  • Administration Requirement: To diminish the potential for gastric irritation, the tablet should preferably be taken after meals as noted in official prescribing information.

The regulatory documents define the product’s interaction structure primarily through this additive sedative effect, coupled with explicit timing constraints for diagnostic purposes. No combinations are formally designated as contraindicated based on interaction mechanism alone, and no specific drug interactions altering exposure (AUC/Cmax) are officially listed.

Mechanism of Action

Vestibular Signal and Vascular Tone Modulation

Cinnarizine's mechanism involves non-competitive blockade of voltage-gated calcium channels and Histamine H1 receptor antagonism. The calcium channel blockade primarily occurs in the small blood vessels of the inner ear and brain, where it induces vasorelaxation, leading to increased localized microcirculation. Simultaneously, the molecule dampens the excitability of the vestibular sensory hair cells by limiting Ca^2+ ion influx, reducing the afferent signal transmission rate from the inner ear's vestibular organs to the central nervous system. This peripheral action is critical for modulating vestibular input.


Central Neurotransmitter Pathway Dampening

In the central nervous system, Cinnarizine's H1 antagonism, coupled with its affinity for Dopamine D2 and Muscarinic Acetylcholine receptors ( M ACh), modulates key neurotransmitter systems. This action reduces the transmission of signals through pathways associated with the brainstem's emetic center, resulting in reduced excitability within the vestibular-associated central pathways. These dual central and peripheral actions collectively modulate the processing of vestibular information at multiple levels.

Dosage and Administration Information

How to Use Cinnarizine (Cinarin) — Administration Guidelines

Cinnarizine is an oral medication available as tablets, with common strengths including 15 mg, 25 mg, and 75 mg. Proper administration helps ensure effective use while minimizing the potential for gastrointestinal discomfort.

Administration Method and Timing

  • Route of Administration: Oral (by mouth).
  • With Meals: Cinnarizine tablets should preferably be taken after meals to diminish gastric irritation.

Standard Dosing for Disorders of Balance

Age Group Standard Dose (e.g., 25 mg tablets) Maximum Daily Dose (All Uses)
Adults (≥ 12 years) One 25 mg tablet three times daily, or 75 mg once a day Should not exceed 225 mg
Children 8 to 12 years Half the adult dose (e.g., 12.5 mg) Consult a healthcare professional

Special Dosing for Motion Sickness

To prevent motion sickness, the first dose must be taken half an hour to two hours before the start of the journey. Dosing may be repeated every 6 to 8 hours during the journey if needed.

Procedural Constraints

  • Skin Testing: Due to its antihistamine effect, Cinnarizine may prevent a positive reaction to dermal reactivity indicators; therefore, its use should be suspended for at least 4 days prior to a skin allergy test.
  • Missed Dose: If a dose is missed, omit the missed dose and continue with the next scheduled dose at the usual time; do not take a double dose to make up for a forgotten one.

Recent Clinical Evidence

Cinarin: Recent Clinical Evidence

Evidence for Symptomatic Management of Vertigo

Research regarding Cinnarizine was studied for its use in populations examined for vertigo and related balance issues. These studies often employ short-term Randomized Controlled Trials (RCTs) that monitor patterns in symptom severity. Research examined patient-reported outcomes describing perceived discomfort, such as measurements of vertigo scores and associated symptoms like nausea. Studies explored Cinnarizine in various conditions characterized by fluctuating or episodic manifestations, including both peripheral and central vestibular disorders.

Systematic reviews note that evidence quality varies across studies. Findings have been mixed regarding the consistency of results in earlier trials that explored Cinnarizine as a single-ingredient medicine. Evidence for monotherapy is often limited relative to trials that have explored Cinnarizine in combination with other active substances.

Evidence for Use in Motion Sickness Prevention

Cinnarizine was studied for its potential role in research exploring prevention of motion-induced symptoms, such as travel sickness. Studies explored the drug primarily through controlled clinical trials, often comparing Cinnarizine to a placebo. Outcomes describing acute changes were monitored, focusing on the occurrence of nausea and vomiting during motion exposure. Findings describe patterns observed between groups that received Cinnarizine versus control groups.

Data in this context are largely focused on prevention. Evidence is less extensive for exploring relief of already-established, severe motion sickness symptoms.

Research Gaps and Uncertainty

Most clinical trials for Cinnarizine were designed to explore short-term symptom changes, with follow-up durations typically limited to a few weeks. Consequently, long-term effects are not fully established, and research provides limited insight into the durability of observed symptomatic patterns over extended periods.

Research in specific populations, such as older adults or those with complex medical histories, is often based on studies with modest sample sizes. This means data for certain subgroups remain insufficient, and results apply primarily to the specific populations studied. Key uncertainties remain regarding the full impact of Cinnarizine monotherapy compared to its frequent combination use.

Key Studies & References

  1. N07CA02 - Cinnarizine (WHO ATC Index)

Frequently Asked Questions (FAQ)

Common questions about Cinarin (FAQ)

Q: Does Cinarin need to be taken at a specific time of day?

Official product information states that Cinarin tablets should preferably be taken after meals. Taking the medicine this way is intended to help reduce the possibility of stomach irritation. Beyond this, specific general times of the day (such as morning or evening) are not typically specified in the regulatory guidelines for daily doses.

Q: Are there any foods or drinks that should be avoided while using Cinarin?

Regulatory documents state that use with alcohol is advised with caution, as it may increase the sedative effect (sleepiness) of the medication. No specific food interactions are commonly listed. However, official prescribing information notes that the medicine should preferably be taken after meals to reduce gastric irritation.

Q: Is Cinarin safe to use for older adults (seniors)?

Official product information notes that use in the elderly requires caution, especially during prolonged treatment. This is due to a heightened risk of developing extrapyramidal symptoms, which are issues related to body movement and muscle control. This conditional use reflects the need for careful monitoring.

Q: Does taking Cinarin affect blood pressure readings?

Regulatory information describes Cinarin as having no known significant systemic blood pressure lowering effects. However, official documents note that caution is advised for people with pre-existing low blood pressure (hypotension). Cinarin is known to induce vasorelaxation, primarily in localized areas.

Q: Is it true that Cinarin has been studied for uses beyond its main approved purpose?

Regulatory documents list Cinarin's officially approved indications, which typically include disorders of balance and the prevention of motion sickness. Any use outside of these approved indications is considered off-label and is not discussed within the official product information provided by regulatory agencies.

Q: Are there any restrictions on activity or exercise while taking Cinarin?

Because Cinarin may cause drowsiness, regulatory documents state that individuals who experience this side effect should avoid driving or operating heavy machinery. Official guidance does not list specific restrictions regarding routine exercise or general physical activity.

Q: Is Cinarin approved by major regulatory bodies like the FDA or EMA?

Cinnarizine is approved and regulated for use by numerous international bodies, including the UK's MHRA/HPRA and other national health authorities across Europe, aligning with EMA guidance. Product status and availability vary by country; for example, Cinnarizine is not currently FDA-approved in the United States.

Q: Can Cinarin affect mood or mental state?

The most common effect Cinarin has on the central nervous system is drowsiness (somnolence). Official product information warns that taking Cinarin with other sedating substances, such as alcohol, can increase this sleepiness. No other specific mood effects are routinely listed as common adverse reactions.

Q: Are there certain common medical conditions (like diabetes or kidney issues) that affect eligibility for Cinarin?

Official regulatory documents advise caution for patients with existing kidney problems (renal insufficiency) and liver problems (hepatic insufficiency). Diabetes is not routinely listed among the conditions requiring specific caution in the standard product information.

Q: Is Cinarin described as being well-tolerated in clinical studies?

Regulatory documents note that the most frequently reported adverse reactions are typically mild and transient. These commonly cited effects include drowsiness, nausea, and weight gain. This pattern suggests that most side effects are not severe.

Q: Does Cinarin interact with herbal products or vitamins?

Due to the potential for increased sedative effects, official guidance advises that patients should check with a healthcare professional before combining Cinarin with herbal products or supplements. This is particularly advised for any supplement that may independently cause sleepiness or dry mouth.

Q: What is the typical timeframe for someone to use Cinarin?

The timeframe for Cinarin use depends on the condition being addressed, as treatment duration varies by individual clinical need. Official documents note that most clinical trials for the medicine have been short-term. Long-term use requires monitoring due to the risk of serious side effects, such as movement disorders.

Q: How long does it usually take to notice an effect from Cinarin?

For the prevention of motion sickness, the initial dose is required to be taken up to two hours before the start of a journey, according to patient information leaflets. The onset of the full symptomatic management effect for balance disorders is not precisely defined in regulatory documents and may vary.

Q: Is Cinarin known to interact with common pain relievers like ibuprofen or acetaminophen?

General patient advice often describes Cinarin as having no known interactions with common non-prescription pain relievers like paracetamol (acetaminophen) or ibuprofen. However, patients are generally advised in official guidance to check with a healthcare professional regarding all current medications.

Q: Is Cinarin a prescription-only medicine?

The regulatory status of Cinnarizine varies globally. In many countries, it is available over-the-counter (OTC) for the purpose of motion sickness prevention. For other conditions, such as vertigo, a prescription may be required.

Q: What should I do if a side effect from Cinarin seems minor but is bothering me?

Regulatory patient information advises communication with a doctor, pharmacist, or nurse if a side effect is experienced, even if minor. These healthcare professionals are the appropriate source for factual guidance regarding treatment.

Q: Is Cinarin considered a habit-forming or addictive drug?

Based on health service guidance, Cinnarizine is not generally considered to be a habit-forming substance. It is not listed as a drug with a high potential for dependence or addiction.

Q: If I am taking multiple medications, how can I find information about Cinarin's interactions?

The primary resource for information about personalized interactions is a healthcare professional. Official patient leaflets state that individuals should inform a doctor or pharmacist about all prescription medications, over-the-counter medicines, supplements, and herbal remedies being taken.

Q: Why is Cinarin sometimes described with the word 'selective'?

Official regulatory documents describe Cinarin's mechanism of action as acting on vascular smooth muscle by selectively inhibiting the influx of calcium. This 'selective inhibition' means it primarily targets certain calcium channels in specific cells, such as those in the inner ear.

Q: Is there a generic version of Cinarin available?

Yes, the active ingredient, Cinnarizine, is available as a generic medicine. Regulatory and government drug registration portals list Cinnarizine alongside various brand names, making it widely accessible.

Q: What is the expected duration of Cinarin's effects after taking it?

The elimination half-life, which is the time it takes for half the drug to be removed from the bloodstream, is reported in official documents to range broadly from 3 to 24 hours. The duration of effect can vary, but peak plasma levels are typically reached 1 to 4 hours after taking the tablet.

Q: Are there any known genetic factors that influence how a person responds to Cinarin?

Official pharmacological information indicates that Cinarin is extensively metabolized in the liver, primarily through the CYP2D6 enzyme. Regulatory documents describe the rate of metabolism by this enzyme as potentially showing considerable interindividual variation.

Q: How quickly is Cinarin removed from the body?

Cinarin is metabolized, and the resulting breakdown products are removed from the body through excretion. Official product information states that approximately one-third of the metabolites are eliminated via the urine, and two-thirds are eliminated through the faeces.

How should Cinarin be stored and disposed of?

How to Store and Dispose of Cinnarizine

Official regulatory documents define specific, mandatory conditions for storing and disposing of Cinnarizine tablets.

Storage Conditions

Requirement Official Statement
Temperature Store at temperatures not exceeding 30°C
Environment The product must be protected from light and kept in a dry place.
Container Keep the tablets in their original container or package.
Child Safety Keep out of the sight and reach of children.

The stability and shelf-life of the medication are maintained when these environmental controls are strictly followed.

Disposal Requirements

Any unused or expired product must be disposed of in accordance with local requirements. Official guidelines typically advise against disposing of the medication via wastewater or routine household trash, supporting appropriate pharmaceutical waste management procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinarin found in:

A-Z Index: